Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
Surgical removal of the thymus gland. (Dorland, 28th ed)
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
An encapsulated lymphatic organ through which venous blood filters.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
Dermatologic disorders attendant upon non-dermatologic disease or injury.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
Stable chromium atoms that have the same atomic number as the element chromium, but differ in atomic weight. Cr-50, 53, and 54 are stable chromium isotopes.
The transference of a kidney from one human or animal to another.
Stable iodine atoms that have the same atomic number as the element iodine, but differ in atomic weight. I-127 is the only naturally occurring stable iodine isotope.

Immunological control of a murine gammaherpesvirus independent of CD8+ T cells. (1/1079)

Adult thymectomized C57 BL/6J mice were depleted of T cell subsets by MAb treatment either prior to, or after, respiratory challenge with murine gammaherpesvirus-68. Protection against acute infection was maintained when either the CD4+ or the CD8+ T cell population was greatly diminished, whereas the concurrent removal of both T cell subsets proved invariably fatal. The same depletions had little effect on mice with established infection. The results indicate firstly that both CD4+ and CD8+ T cells play a significant part in dealing with the acute infection, and secondly that virus-specific antibody contributes to controlling persistent infection with this gammaherpesvirus.  (+info)

Long-term results of pancreas transplantation under tacrolius immunosuppression. (2/1079)

BACKGROUND: The long-term safety and efficacy of tacrolimus in pancreas transplantation has not yet been demonstrated. The observation of prolonged pancreatic graft function under tacrolimus would indicate that any potential islet toxicity is short-lived and clinically insignificant. We report herein the results of pancreas transplantation in patients receiving primary tacrolimus immunosuppression for a minimum of 2 years. METHODS: From July 4, 1994 until April 18, 1996, 60 patients received either simultaneous pancreas-kidney transplant (n=55), pancreas transplant only (n=4), or pancreas after kidney transplantation (n=1). Baseline immunosuppression consisted of tacrolimus and steroids without antilymphocyte induction. Azathioprine was used as a third agent in 51 patients and mycophenolate mofetil in 9. Rejection episodes within the first 6 months occurred in 48 (80%) patients and were treated with high-dose corticosteroids. Antilymphocyte antibody was required in eight (13%) patients with steroid-resistant rejection. RESULTS: With a mean follow-up of 35.1+/-5.9 months (range: 24.3-45.7 months), 6-month and 1-, 2-, and 33-year graft survival is 88%, 82%, 80%, and 80% (pancreas) and 98%, 96%, 93%, and 91% (kidney), respectively. Six-month and 1-, 2-, and 3-year patient survival is 100%, 98%, 98%, and 96.5%. Mean fasting glucose is 91.6+/-13.8 mg/dl, and mean glycosylated hemoglobin is 5.1+/-0.7% (normal range: 4.3-6.1%). Mean tacrolimus dose is 6.5+/-2.6 mg/day and mean prednisone dose 2.0+/-2.9 mg/day at follow-up. Complete steroid withdrawal was possible in 31 (65%) of the 48 patients with functioning pancreases. CONCLUSIONS: These data show for the first time that tacrolimus is a safe and effective long-term primary agent in pancreas transplantation and provides excellent long-term islet function without evidence of toxicity while permitting steroid withdrawal in the majority of patients.  (+info)

Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. (3/1079)

We report the results of the first prospective randomized multicenter study of immunosuppressive treatment in patients with previously untreated nonsevere aplastic anemia (AA) as defined by a neutrophil count of at least 0.5 x 10(9)/L and transfusion dependence. Patients were randomized to receive cyclosporin (CSA) alone or the combination of horse antithymocyte globulin ([ATG] Lymphoglobuline; Merieux, Lyon, France) and CSA. The endpoint of the study was the hematologic response at 6 months. One hundred fifteen patients were randomized and assessable with a median follow-up period of 36 months; 61 received CSA and 54 ATG and CSA. In the CSA group, the percentage of complete and partial responders was 23% and 23%, respectively, for an overall response rate of 46%. A significantly higher overall response rate of 74% was found in the ATG and CSA group, with 57% complete and 17% partial responders (P =. 02). Compared with CSA alone, the combination of ATG and CSA resulted in a significantly higher median hemoglobin level and platelet count at 6 months. Fewer patients required a second course of treatment before 6 months due to a nonresponse. In the CSA group, 15 of 61 (25%) patients required a course of ATG before 6 months because of disease progression, compared with only 3 of 54 (6%) in the ATG and CSA group. The survival probabilities for the two groups were comparable, 93% (CSA group) and 91% (ATG and CSA group), but at 180 days, the prevalence of patients surviving free of transfusions, which excluded patients requiring second treatment because of nonresponse, death, disease progression, or relapse, was 67% in the CSA group and 90% in the ATG and CSA group (P =.001). We conclude that the combination of ATG and CSA is superior to CSA alone in terms of the hematologic response, the quality of response, and early mortality, and a second course of immunosuppression is less frequently required.  (+info)

Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. (4/1079)

To determine whether the antigen-driven T-cell response is involved in the pathogenesis of aplastic anemia (AA), we examined the complementarity-determining region 3 (CDR3) size distribution of T-cell receptor (TCR) beta-chain (BV) subfamilies in the bone marrow (BM) of untreated AA patients. AA patients who did not respond to immunosuppressive therapy and those who obtained unmaintained remission early after cyclosporine (CyA) or antithymocyte globulin (ATG) therapy exhibited essentially a normal CDR3 size pattern. In contrast, five patients who needed continuous administration of CyA to maintain remission exhibited a skewed CDR3 size pattern in a number (>40%) of BV subfamilies suggestive of clonal predominance. The skewing of CDR3 size distribution became less pronounced in one of the CyA-dependent patients when the patient achieved unmaintained remission after a 4-year therapy with CyA, whereas it persisted longer than 7 years in the other patient requiring maintenance therapy. Sequencing of BV15 cDNA for which the CDR3 size pattern exhibited apparent clonal predominance in all CyA-dependent patients showed high homology of the amino acid sequence of the CDR3 between two different patients. These findings indicate that antigen-driven expansion of T cells is involved in the pathogenesis of AA characterized by CyA-dependent recovery of hematopoiesis.  (+info)

Late graft failure 8 years after first bone marrow transplantation for severe acquired aplastic anemia. (5/1079)

A 14-year-old patient with acquired very severe aplastic anemia (VSAA) underwent bone marrow transplantation (BMT) from his HLA-identical brother. Preparative therapy was cyclophosphamide (CY) 200 mg/kg over 4 days. GVHD prophylaxis was with cyclosporin A (CsA) for a year. After an 8 year follow-up during which the patient was well with normal blood counts, graft failure occurred. At this time marrow chimerism studies demonstrated that 85% of hemopoiesis was of recipient origin. The patient was re-engrafted from the same donor after conditioning with CY 200 mg/kg over 4 days plus rabbit antithymocyte globulin (ATG) 3.5 mg/kg/day for 3 days. After 140 days follow-up he has a normal blood count. The possible causes of the graft failure are discussed. This case demonstrates that, although rarely, very late graft failure may occur after BMT for AA and highlights the need for long-term monitoring even in apparently successfully transplanted patients.  (+info)

Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. (6/1079)

The present study was undertaken to acquire a rationale for clinical dose adjustment of anti-thymocyte globulin (ATG) to improve cost effectiveness and safety of graft-versus-host disease prophylaxis. The concentration of rabbit ATG in the serum of 12 patients was measured by ELISA and by the inhibitory effect on phytohaemagglutinin-induced blastogenesis. At 10 mg/ml ATG, 3H-thymidine incorporation was effectively blocked. Serial two-fold dilution of ATG showed that this effect decreased in a concentration-dependent manner and was lost at 10 ng/ml ATG. One hundred microlitres serum taken at day -1 to +22 post transplant effected significant inhibition of the phytohaemagglutinin-response with 49+/-12% c.p.m. (x +/- s.d.) on day +1 post transplant compared to 93+/-13% c.p.m. on day -1 (P<0.001, unpaired one-sided t-test). The rabbit-IgG was maximal at a concentration of 907+/-187 microl/ml at day 0. Subsequently, it decreased with time. While rabbit-IgG was detectable for a long period (e.g. 160 microg/ml at day +22 in patient MD), the effect on the phytohaemagglutinin-response of normal mononuclear cells lasted up to 4 days post transplant. We conclude that 90 mg/kg body weight ATG-Fresenius given prior to marrow transplant leads to sustained T cell immunosuppression post transplant.  (+info)

Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow. (7/1079)

A five-agent GVHD prophylaxis programme consisting of cyclosporin A, methotrexate, anti-thymocyte-globulin, pentaglobin and metronidazol was given to 48 recipients of unrelated donor marrow with chronic myelogenous leukemia, acute leukemia, myelodysplastic syndromes, and familiar lymphocytic hemophagocytosis of an average age of 33.5 (0.6-56) years. GVHD grades II-IV occurred in 18 patients (39%) and grades III-IV in five patients (11%). Chronic GVHD developed in nine patients (23%), three limited and six extensive. Fifteen patients died. Clinical relapse was detected in eight patients. Four patients died as a consequence of the underlying disease and subsequent treatment, 11 patients died of transplant-related causes. After a median follow-up of 19 months, the overall and disease-free survival are 67% and 62%, respectively. Survival by age is as follows: 0-19 years: 12/13 patients; 20-39 years: 14/25 patients; 40-59 years: 7/10 patients. The five-agent GVHD prophylaxis regimen is effective. Matched-unrelated donor transplants can be carried out safely in patients younger than 50 years of age. The results in patients younger than 20 years of age should encourage matched-unrelated donor transplants at earlier stages of the disease.  (+info)

L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. (8/1079)

BACKGROUND: Mesangial cell lysis in the antithymocyte serum (ATS)-induced model of glomerulonephritis is dependent on the generation of cytotoxic nitric oxide (NO) through transient induction of NO synthase (iNOS). We hypothesized that increased availability of L-arginine (L-Arg) during mesangial cell lysis might provide iNOS with increased substrate leading to increased lysis, and that this increased lysis would be reflected in more severe fibrotic disease at day 6. METHODS: To ensure whole body equilibration with high L-Arg at the time of injury, rats were pretreated with 1% L-Arg in drinking water for one week prior to the administration of ATS. Animals were sacrificed six hours after ATS injection when previous experiments had indicated iNOS induction had occurred and at six days. At six hours, plasma was obtained for L-Arg levels and nitrite/nitrate (NOx) content. Renal tissues were taken for histological evaluation of glomerular cell counts, macrophage infiltration (ED-1), and iNOS expression. Glomeruli were isolated for detection of iNOS mRNA and placed in culture to study the dependence of NO production on L-Arg concentration. In rats sacrificed at six days, L-Arg supplementation was stopped 16 hours after ATS injection. Fibrotic disease was evaluated by urinary protein excretion, histological assessment of glomerular cell number, matrix accumulation, and production of transforming growth factor-beta1 and matrix components fibronectin and plasminogen activator inhibitor type-1 (PAI-1) by isolated glomeruli in culture. RESULTS: At six hours, the glomerular cell number was significantly reduced by ATS injection (P < 0.01) and further significantly (P < 0. 05) reduced by L-Arg feeding [normal control (NC) = 64.2 +/- 1, ATS = 53.4 +/- 0.7, ATS + L-Arg = 50.8 +/- 0.7]. Disease increased macrophage infiltration and iNOS protein and iNOS mRNA levels markedly (P < 0.01), whereas L-Arg feeding did not further increase these variables. Plasma L-Arg levels (nmol/ml) were reduced by disease (NC = 121 +/- 9, ATS = 84 +/- 13, P < 0.01) and elevated by L-Arg feeding (ATS + L-Arg = 166 +/- 12, P < 0.01). Plasma NOx was significantly increased by ATS and further increased by ATS + L-Arg (P < 0.05). Production of NOx by cultured glomeruli showed striking L-Arg concentration dependence in six hours but not in normal glomeruli. In the group sacrificed at day 6, day 2 proteinuria was higher in the ATS + L-Arg group compared with the ATS alone group (P < 0.05). Measures of fibrotic disease at day 6 all showed large increases over control with ATS alone (P < 0.01), and further small, but significant increases when L-Arg was combined with ATS (P < 0.05). CONCLUSIONS: The results indicate that if given during disease induction, L-Arg supplementation can enhance iNOS-dependent tissue injury by providing increased substrate. Although the increase in injury with L-Arg supplementation was small, it led to increased fibrosis at day 6. These data predict that in diseases with repeated iNOS-dependent tissue injury, L-Arg supplementation may produce cumulative increases in tissue fibrosis.  (+info)

Symptoms of aplastic anemia may include fatigue, weakness, shortness of breath, pale skin, and increased risk of bleeding or infection. Treatment options for aplastic anemia typically involve blood transfusions and immunosuppressive drugs to stimulate the bone marrow to produce new blood cells. In severe cases, a bone marrow transplant may be necessary.

Overall, aplastic anemia is a rare and serious condition that requires careful management by a healthcare provider to prevent complications and improve quality of life.

* Rashes, lesions, or sores
* Redness, swelling, or inflammation
* Skin thickening or thinning
* Pigmentation changes
* Growths or tumors
* Ulcers or wounds that do not heal properly

Skin manifestations can be a symptom of a wide range of medical conditions, including:

* Infections such as bacterial, fungal, or viral infections
* Autoimmune disorders such as psoriasis, eczema, or lupus
* Cancer such as melanoma, squamous cell carcinoma, or basal cell carcinoma
* Genetic conditions such as ichthyosis or epidermolysis bullosa
* Metabolic disorders such as diabetes or kidney disease
* Nutritional deficiencies such as vitamin deficiency or malnutrition

Skin manifestations can be diagnosed through a combination of physical examination, medical history, and diagnostic tests such as biopsy, blood tests, or imaging studies. Treatment options vary depending on the underlying condition and may include topical medications, systemic medications, surgery, or lifestyle changes.

In some cases, skin manifestations can be a sign of a more serious underlying condition that requires prompt medical attention. It is important to seek medical advice if you notice any unusual changes in your skin or if you experience any symptoms such as pain, itching, or bleeding.

... antilymphocyte sera, monoclonal antibodies against Tlymphocytes). He has been interested in the mechanisms and treatments of ...
"Improved graft survival after treatment with Bordetella and anti-lymphocyte serum". Nature. 222 (5198): 1083-5. Bibcode: ... Ptak W, Porwit-Bóbr Z, Chlap Z (1970). "Transformation of hamster macrophages into giant cells with antimacrophage serum". ...
Peter Medawar gave a lecture entitled "Anti-lymphocyte serum" in May 1967; Henry Harris discussed "The expression of genetic ...
Among these contributions, Woodruff's work with anti-lymphocyte serum has led to its wide use to reduce rejection symptoms in ... Woodruff also commenced work on antilymphocyte serum for immunosuppression, with little initial success. While in Aberdeen, ...
Later during the treatment, some patients develop serum sickness or immune complex glomerulonephritis. Serum sickness arises ... The antilymphocyte (ALG) and antithymocyte antigens (ATG) are being used. They are part of the steroid-resistant acute ... As of March 2005, there are two preparations available to the market: Atgam, obtained from horse serum, and Thymoglobuline, ... It is possible to diminish their toxicity by using highly purified serum fractions and intravenous administration in the ...
Since the discovery of a link between antilymphocyte serum (ALS) and lymphocyte depletion by Metchnikoff in 1899, various ... Antithymocyte globulin (ATG) was originally developed as one of various tested preparations of antilymphocyte globulin (ALG) ... leading to testing of ATG derived from rabbit serum. Thymoglobulin was the first commercial rabbit-derived ATG to be introduced ...
... (ALG) is an infusion of animal- antibodies against human T cells which is used in the treatment of ... The product was manufactured by Upjohn and Merieux, as well as the Schweizerisches Serum- und Impfinstitut in Bern, the latter ... "Guillain Barré syndrome precipitated by the use of antilymphocyte globulin in the treatment of severe aplastic anaemia". J. ... Treatment of aplastic anaemia by antilymphocyte glubulin with and without allogeneic bone marrow infusions, in Lancet (1977) 2: ...
... immune sera MeSH D12.776.377.715.548.114.573.203 - antilymphocyte serum MeSH D12.776.377.715.548.114.580 - immunoconjugates ...
... immune sera MeSH D12.776.124.486.485.114.573.203 - antilymphocyte serum MeSH D12.776.124.486.485.114.573.601 - antitoxins MeSH ... immune sera MeSH D12.776.124.790.651.114.573.203 - antilymphocyte serum MeSH D12.776.124.790.651.114.580 - immunoconjugates ...
... serum MeSH A12.207.152.846.500 - immune sera MeSH A12.207.152.846.500.203 - antilymphocyte serum MeSH A12.207.180 - body fluid ...
... immune sera MeSH D20.215.401.203 - antilymphocyte serum MeSH D20.215.535 - menotropins MeSH D20.215.659 - picibanil MeSH ...
When he subsequently collected serum from these Guinea pigs and injected it into normal mice he observed a marked depletion in ... A similar trial of anti-lymphocyte globulin showed a trend in reduction of acute graft versus host that was not statistically ...
Additionally, blood serum should be tested for the presence of viruses, including HIV, hepatitis B and C, cytomegalovirus (CMV ... They may also be treated with anti-lymphocyte antibodies (anti-thymocyte globulin, alemtuzumab), irradiation directed against ... and serum pH and lactate levels measured for evidence of intestinal ischemia. The patient's immune system is strongly modulated ...
Negative sera from patients with other autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, and multiple ... First-line treatment for aplastic anemia consists of immunosuppressive drugs-typically either anti-lymphocyte globulin or anti- ... Corticosteroids are generally ineffective, though they are used to ameliorate serum sickness caused by ATG. Normally, success ... more than 30 potential specific candidate autoantigens after the serologic screening of a fetal liver library with sera from 8 ...
Antilymphocyte Serum. Immunosuppressive Agents. Immunologic Factors. Physiological Effects of Drugs. Antirheumatic Agents. ... 3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. ... 3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. ... 3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. ...
Immunosuppression of mice with antilymphocyte serum (ALS) or irradiation increased tumor incidence in mice inoculated with 1 X ...
Antilymphocyte Globulins. Antilymphocyte Immunoglobulin. Antilymphocyte Immunoglobulins. Antilymphocyte Serums. Antithymocyte ... Antibodies, Antilymphocyte Antibody, Antilymphocyte Antilymphocyte Antibody Antilymphocyte Globulin - Narrower Concept UI. ... Serum, Antilymphocyte. Serums, Antilymphocyte. Tree number(s):. A12.207.152.846.500.203. D12.776.124.486.485.114.573.203. ... Antilymphocyte Serum - Preferred Concept UI. M0001464. Scope note. Serum containing GAMMA-GLOBULINS which are antibodies for ...
Group 2 was treated with short-term antilymphocyte serum (ALS) and cyclosporine-A (CsA). Group 3 was administrated CD26i and G- ... No statistically significant differences were found in hemoglobin (HB), total serum protein (TP), serum albumin (ALB), ... and rats were treated with ASCs combined with short-term treatment with anti-lymphocyte serum (ALS)/cyclosporine (CsA) as ... It also increased the proportion of some beneficial metabolites in the serum, such as arachidonic acid, tryptophan hydroxylase ...
Brummelhuis have prepared antilymphocyte globulin (ALG), an immunosuppressive agent, from horse antihuman lymphocyte sera. ... Using this technique, tetanus toxin, diptheria toxoid and human serum globulin have been fractionated. Mathies obtained a 3- ... with the notable exception of serum fractionation. In this process, despite the introduction of other techniques, ethanol ...
Antilymphocyte Serum * Bone Marrow Transplantation * Child * Child, Preschool * Graft vs Host Disease ...
Normal serum creatinine and absence of proteinuria are good screening parameters to identify patients at low risk for acute ... The first polyclonal antilymphocyte globulin was used in 1967 and spawned the development of other polyclonal and monoclonal ... Polyclonal antilymphocyte antibodies were first successfully used in the 1970s in organ transplantation; however, 10 years ... Heterologous antilymphocyte glubulin, histoincompatiblity matching, and human renal homotransplantation. Surg Gynecol Obstet. ...
Serum glutamic pyruvic transaminase?SGRQ: St. Georges Respiratory Questionnaire?SH: Social history?SH: Serum hepatitis?SHBG: ... Antilymphocyte globulin?ALL: Acute lymphoblastic leukemia?ALLHAT: Antihypertensive Lipid Lowering Heart Attack Trail?ALT: ... CD: Crohn\s disease?(R): Right?/d: Per day?1/ SCr: Inverse of serum creatinine?1/2NS: Half-strength normal saline?3D CRT: ... Radioiodinated serum albumin?RK: Right kidney?RL: Right leg?RL: Right lung?RLC: Residual lung capacity?RLD: Related living ...
Serum-ionized calcium is normal or slightly decreased. PTH concentration is elevated, although reports are conflicting. Serum 1 ... The safety of antilymphocyte antibodies and rituximab is not well established in pregnancy (287). ... Significant elevations in serum creatinine (e.g., ,1.5 mg/dL) are unusual in women with preeclampsia, particularly if BP is ... Both total serum calcium (Ca) and albumin decrease in pregnancy; however, ionized Ca remains unchanged (146,147). An increase ...
Woo J, Zhang W, Gao L, Shen J, Chong A, Buelow R. Combination of antilymphocyte globulin and leflunomide leads to superior ... Sankary H, Chong A, Frye E, Scuderi P, Foster P, McChesney L, Williams J. Daily determinations of serum lymphotoxin allows for ...
Twenty-two patients with aplastic anemia were treated with antilymphocyte serum or antithymocyte globulin at Vanderbilt ... Re-treatment of aplastic anemia with antithymocyte globulin or antilymphocyte serum R T Means Jr 1 , S B Krantz, E N Dessypris ... Re-treatment of aplastic anemia with antithymocyte globulin or antilymphocyte serum R T Means Jr et al. Am J Med. 1988 Apr. ... Clinical experience with antilymphocyte serum. Heyworth MF. Heyworth MF. Immunol Rev. 1982;65:79-97. doi: 10.1111/j.1600-065x. ...
Effect of heterologous antilymphocyte serum on the spontaneous cure of Trichinella spiralis infections in mice ... Effect of heterologous antilymphocyte serum on the spontaneous cure of Trichinella spiralis infections in mice J DiNetta, F ... Effect of heterologous antilymphocyte serum on the spontaneous cure of Trichinella spiralis infections in mice J DiNetta et al. ... Trichinella spiralis: influence of antilymphocytic serum on mouse infections. Machnicka B. Machnicka B. Exp Parasitol. 1972 Apr ...
Serum amylase may double or triple with rejection; however, an elevated serum amylase level may also indicate pancreatitis. In ... He was treated with an antilymphocyte agent (8 doses). A biopsy 2 weeks after transplantation showed histologic resolution of ... At the 2-week follow-up appointment, his lab value (serum amylase, lipase, and glucose) were normal, but his biopsy showed ... Careful attention to fasting blood glucose levels and upward trends in serum amylase, lipase, and glucose levels may be useful ...
Re-treatment of aplastic anemia with antithymocyte globulin or antilymphocyte serum. Am J Med. 1988 Apr. 84(4):678-82. [QxMD ... Treatment of aplastic anemia with an investigational antilymphocyte serum prepared in rabbits. Am J Med Sci. 1994 Dec. 308(6): ... Liu H, Mihara K, Kimura A, Tanaka K, Kamada N. Induction of apoptosis in CD34+ cells by sera from patients with aplastic anemia ... Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood. 1987 Oct. 70(4):1046-52 ...
... antilymphocyte sera and antimetabolites. While the specific molecular action of many of these drugs is known, how they affect ... Based on an earlier described macromethod for the routine measurement of IgM and IgG in rat sera, a mechanized micro enzyme- ... Mice exposed to dichloroethane in the drinking water for 90 days showed no alteration in AFC, serum antibody titers or response ... A multitude of immunoassays have been developed for enumeration of serum antibody. Some of these are immunodiffusion, ...
Renal and liver functions should be assessed repeatedly by measurement of BUN, serum creatinine, serum bilirubin, and liver ... antilymphocyte globulin. A form of chronic progressive cyclosporine-associated nephrotoxicity is characterized by serial ... Methanol will be present in human milk at levels similar to that found in maternal serum and if present in breast milk will be ... Clinical status and serum creatinine should be closely monitored when cyclosporine is used with NSAIDs in rheumatoid arthritis ...
Re-treatment of aplastic anemia with antithymocyte globulin or antilymphocyte serum. Am J Med. 1988 Apr. 84(4):678-82. [QxMD ... Treatment of aplastic anemia with an investigational antilymphocyte serum prepared in rabbits. Am J Med Sci. 1994 Dec. 308(6): ... Liu H, Mihara K, Kimura A, Tanaka K, Kamada N. Induction of apoptosis in CD34+ cells by sera from patients with aplastic anemia ... Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood. 1987 Oct. 70(4):1046-52 ...
Serum A12.207.152.846.500 Immune Sera A12.207.152.846.500.203 Antilymphocyte Serum A12.207.180 Body Fluid Compartments A12.207. ... Serum A15.378 Hematopoietic System A15.378.316 Bone Marrow Cells A15.378.316.340 Granulocytes A15.378.316.340.350 Granulocyte ...
ALG (anti-lymphocyte globulin) -- the gamma globulin fraction of anti-lymphocyte serum, which destroys circulating lymphocytes ...
Serum [A12.207.152.846] * Immune Sera [A12.207.152.846.500] * Antilymphocyte Serum [A12.207.152.846.500.203] ... Antilymphocyte Serum Preferred Concept UI. M0001464. Registry Number. 0. Scope Note. Serum containing GAMMA-GLOBULINS which are ... Immune Sera [D12.776.124.486.485.114.573] * Antilymphocyte Serum [D12.776.124.486.485.114.573.203] ... Immune Sera [D12.776.124.790.651.114.573] * Antilymphocyte Serum [D12.776.124.790.651.114.573.203] ...
Antilymphocyte_Serum,create,29-SEP-06,(null),(null) C691,Nicotine,modify,29-SEP-06,(null),(null) C62055,Naltrexone_Base,modify, ... Antilymphocyte_Serum,create,29-SEP-06,(null),(null) C691,Nicotine,modify,29-SEP-06,(null),(null) C62055,Naltrexone_Base,modify, ...
Anti Lymphocyte serum, 1968-1972 File - Box: 17, Folder: 20 Scope and Contents From the Series: This series provides details on ...
Antilymphocyte Globulins. Antilymphocyte Immunoglobulin. Antilymphocyte Immunoglobulins. Antilymphocyte Serums. Antithymocyte ... Antibodies, Antilymphocyte Antibody, Antilymphocyte Antilymphocyte Antibody Antilymphocyte Globulin - Narrower Concept UI. ... Serum, Antilymphocyte. Serums, Antilymphocyte. Tree number(s):. A12.207.152.846.500.203. D12.776.124.486.485.114.573.203. ... Antilymphocyte Serum - Preferred Concept UI. M0001464. Scope note. Serum containing GAMMA-GLOBULINS which are antibodies for ...
Serum [A12.207.152.846] * Immune Sera [A12.207.152.846.500] * Antilymphocyte Serum [A12.207.152.846.500.203] ... Antilymphocyte Serum Preferred Concept UI. M0001464. Registry Number. 0. Scope Note. Serum containing GAMMA-GLOBULINS which are ... Immune Sera [D12.776.124.486.485.114.573] * Antilymphocyte Serum [D12.776.124.486.485.114.573.203] ... Immune Sera [D12.776.124.790.651.114.573] * Antilymphocyte Serum [D12.776.124.790.651.114.573.203] ...
... anti-lymphocyte serum ALS,anticipated life span ALS,antilymphocyte serum Am,acto-myosin Am,actomyosin Am,acute myelofibrosis Am ... serum factor SF,serum ferritin SF,serum fibrinogen SF,serum-ferritin SF,serum-free SF,serumfree SF,sexual function SF,sham ... serum creatinine SCR,serum creatinine SCR,serum creatinine SCR,serum creatinine SCR,Sex combs reduced SCR,Sex combs reduced SCR ... anti-macrophage serum A.M.S.,anticoagulation management service A.M.S.,antimacrophage serum A.M.S.,aseptic meningitis syndrome ...
Antilymphocyte serum Active Synonym false false 3669028014 Lymphocyte immunoglobulin product Active Synonym false false ...
Abbreviations for AntiLymphocyte Globulin; AntiLymphocyte Serum. Both are products of animal scrum used to prevent rejection . ...
PMID- 5165171 TI - [Antilymphocyte serum. Effects on blastogenesis and cytotoxic activity of lymphocytes stimulated with ... If, however, the T cells in the spleens of HGG.NIP-primed mice were eliminated by treatment with anti-theta serum and ... A review of 90 cases]. PMID- 5157696 TI - [IgA in the gastric content and in the serum of eutrophic and malnourished infants]. ... PMID- 5165843 TI - pK change of imidazole groups in bovine serum albumin due to the conformational change at neutral pH. PMID- ...
... antilymphocyte globulin antilymphocyte globulins antilymphocytes anti-lymphocytes antilymphocyte sera antilymphocyte serum ... antirabies anti-rabies anti-rabies sera antirabies sera anti-rabies serum antirabies serum anti-rabies serums antirabies serums ... aplastic anaemia sera aplastic anaemia serum aplastic anaemia serums aplastic anemia aplastic anemia sera aplastic anemia serum ... acidified complement acidified complements acidified sera acidified serum acidified serums acidified serum test acidified serum ...
Re-treatment of aplastic anemia with antithymocyte globulin or antilymphocyte serum. Am J Med. 1988 Apr. 84(4):678-82. [QxMD ... Treatment of aplastic anemia with an investigational antilymphocyte serum prepared in rabbits. Am J Med Sci. 1994 Dec. 308(6): ... Liu H, Mihara K, Kimura A, Tanaka K, Kamada N. Induction of apoptosis in CD34+ cells by sera from patients with aplastic anemia ... Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood. 1987 Oct. 70(4):1046-52 ...
Anti-Lymphocyte Antigen 6 Complex, Locus E-. Yip V; Figueroa I; Latifi B; Masih S; Ng C; Leipold D; Kamath A; Shen BQ. Drug ... EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles ...
Renal and liver functions should be assessed repeatedly by measurement of BUN, serum creatinine, serum bilirubin, and liver ... antilymphocyte globulin. A form of chronic progressive cyclosporine-associated nephrotoxicity is characterized by serial ... Methanol will be present in human milk at levels similar to that found in maternal serum and if present in breast milk will be ... Clinical status and serum creatinine should be closely monitored when cyclosporine is used with NSAIDs in rheumatoid arthritis ...
ALG (anti-lymphocyte globulin) -- the gamma globulin fraction of anti-lymphocyte serum, which destroys circulating lymphocytes ...
ALG (anti-lymphocyte globulin) -- the gamma globulin fraction of anti-lymphocyte serum, which destroys circulating lymphocytes ...
ALG (anti-lymphocyte globulin) -- the gamma globulin fraction of anti-lymphocyte serum, which destroys circulating lymphocytes ...
Serum creatinine , 1.5 times the upper limit of normal (ULN). -Hemoglobin , 8 g/dL. -Alanine transaminase or aspartate ... Evidence for autoantibody positivity (eg, ANA or in the research flow method looking for antilymphocyte antibodies). -Female ... Serum IgG , 400 mg/L. -Current use of systemic glucocorticosteroids, with the exception of corticosteroid nasal spray or ...
The pGIA mice received anti-lymphocyte antigen 6 complex locus G6D (Ly6G) antibodies to deplete neutrophils and the expression ... 4 and IL-10 from in vitro stimulated splenocytes and serum anti-H. diminuta IgG. Moreover, mice infected with 5 H. diminuta 28 ... Recombinant ITIH4 and cit-ITIH4 were incubated with sera from healthy volunteers before its chemotactic ability and C5a level ...
IMMUNOLOGIC FACTORS ANTILYMPHOCYTE SERUM IMMUNOLOGIC FACTORS ANTIMICROBIAL CATIONIC PEPTIDES IMMUNOLOGIC FACTORS ... BLOOD PROTEINS SERUM ALBUMIN BLOOD PROTEINS SERUM ALBUMIN, BOVINE BLOOD PROTEINS SERUM ALBUMIN, RADIO-IODINATED BLOOD PROTEINS ... IMMUNOSUPPRESSIVE AGENTS ANTILYMPHOCYTE SERUM IMMUNOSUPPRESSIVE AGENTS AZASERINE IMMUNOSUPPRESSIVE AGENTS AZATHIOPRINE ... IMMUNOLOGIC AND BIOLOGICAL FACTORS ANTILYMPHOCYTE SERUM IMMUNOLOGIC AND BIOLOGICAL FACTORS ANTIMICROBIAL CATIONIC PEPTIDES ...
... anti-lymphocyte serum ALS,anticipated life span ALS,antilymphocyte serum Am,acto-myosin Am,actomyosin Am,acute myelofibrosis Am ... serum factor SF,serum ferritin SF,serum fibrinogen SF,serum-ferritin SF,serum-free SF,serumfree SF,sexual function SF,sham ... serum creatinine SCR,serum creatinine SCR,serum creatinine SCR,serum creatinine SCR,Sex combs reduced SCR,Sex combs reduced SCR ... anti-macrophage serum A.M.S.,anticoagulation management service A.M.S.,antimacrophage serum A.M.S.,aseptic meningitis syndrome ...
  • Twenty-two patients with aplastic anemia were treated with antilymphocyte serum or antithymocyte globulin at Vanderbilt University and affiliated hospitals from 1980 to 1986. (nih.gov)
  • Twenty patients received antilymphocyte serum initially while two patients received antithymocyte globulin. (nih.gov)
  • Fifteen patients received fluoxymesterone 10 mg by mouth three times a day with antilymphocyte serum, and all received prednisone during the course of antilymphocyte serum or antithymocyte globulin. (nih.gov)
  • Eight patients with no initial response and a patient who experienced a relapse after a complete response were re-treated with either antithymocyte globulin (six) or antilymphocyte serum (three), with four of nine patients (44 percent) having a response (three complete responses, one partial response). (nih.gov)
  • The first polyclonal antilymphocyte globulin was used in 1967 and spawned the development of other polyclonal and monoclonal antibodies. (medscape.com)
  • Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS . (nih.gov)
  • Evidence for autoantibody positivity (eg, ANA or in the research flow method looking for antilymphocyte antibodies). (nih.gov)
  • Later studies demonstrated antibodies in the sera of affected patients that reacted with the cross striations of skeletal muscle, as well as muscle membrane damage following the application of myasthenic sera to nerve-muscle preparations. (medlink.com)
  • In 1974, Alman, Andrew, and Appel identified anti-AChR antibodies in human sera ( 04 ), further opening a promising new immunologic frontier in the pathogenesis of human disease. (medlink.com)
  • Immunosuppression of mice with antilymphocyte serum (ALS) or irradiation increased tumor incidence in mice inoculated with 1 X 106 PLC/PRF/5 cells to almost 100% and produced local invasiveness. (jci.org)
  • PMID- 5157696 TI - [IgA in the gastric content and in the serum of eutrophic and malnourished infants]. (nih.gov)
  • Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS . (bvsalud.org)
  • PMID- 5157696 TI - [IgA in the gastric content and in the serum of eutrophic and malnourished infants]. (nih.gov)
  • Most centers include induction therapy with an antilymphocyte agent in their immunosuppressive regimens. (medscape.com)
  • 31. EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy. (nih.gov)
  • Careful attention to fasting blood glucose levels and upward trends in serum amylase, lipase, and glucose levels may be useful in the clinical detection of rejection, but are usually not apparent until late in the rejection process. (medscape.com)
  • In addition, iron chelation may be required in chronically transfused patients who develop elevated serum ferritin levels above 1000 µg/L. (medscape.com)